Morgan Oliver, Griffiths Clare, Hickman Matthew
Department of Primary Care and Social Medicine, Imperial College London, London, UK.
Int J Epidemiol. 2006 Dec;35(6):1579-85. doi: 10.1093/ije/dyl207. Epub 2006 Oct 30.
The UK heroin market is the biggest in Europe and approximately 70% of heroin deaths are due to fatal poisoning. Methadone treatment for heroin addiction in the UK, the 'British system', is unique as it is largely provided by General Practitioners.
The Office for National Statistics provided data on deaths, the Home Office provided law enforcement data on drug seizures and the Department of Health data on prescriptions. For methadone treatment we calculated the death rate per 1000 patient years. We used Spearman's rank correlation to assess the association between illicit drug seizures for heroin and methadone and deaths.
Between 1993 and 2004 there were 7072 deaths involving heroin/morphine (86% males) and 3298 deaths involving methadone (83% male). From 1993-1997, directly age-standardized mortality rates for males were similar for both drugs, increasing from approximately 5 to 15 per million. Mortality rates for heroin continued to increase until 2000, subsequently decreasing from 30 to 20 per million by 2003, and rising again to 24 per million in 2004. In contrast, mortality rates for methadone decreased between 1997 and 2004 to just above 1993 levels. Among females the mortality rate for both drugs was lower than for males throughout the study period, remaining relatively stable. Methadone deaths per 1000 patient years remained similar between 1993 and 1997, after which they fell by three quarters. For both heroin/morphine and methadone, deaths were strongly associated with seizures (Spearmans' coefficient for males: heroin, P = 0.95, P < 0.001 and methadone, P = 0.83, P = 0.0013).
Our study suggests the 'British System' can deliver substantial expansion of treatment without increased mortality risk. The fall in heroin/morphine deaths since 2000 may also be an indication of success of increasing methadone treatment. Data on mortality risk is needed to determine whether increased methadone treatment has reduced drug-related deaths.
英国的海洛因市场是欧洲最大的,约70%的海洛因致死案例是因致命中毒。英国针对海洛因成瘾的美沙酮治疗体系,即“英国体系”,独具特色,因为其主要由全科医生提供。
国家统计局提供死亡数据,内政部提供毒品查获的执法数据,卫生部提供处方数据。对于美沙酮治疗,我们计算了每1000患者年的死亡率。我们使用斯皮尔曼等级相关性来评估海洛因和美沙酮的非法毒品查获量与死亡之间的关联。
1993年至2004年间,有7072例涉及海洛因/吗啡的死亡(86%为男性),3298例涉及美沙酮的死亡(83%为男性)。1993年至1997年,两种药物在男性中的直接年龄标准化死亡率相似,从每百万约5例增至15例。海洛因的死亡率持续上升直至2000年,随后从每百万30例降至2003年的每百万20例,并在2004年再次升至每百万24例。相比之下,美沙酮的死亡率在1997年至2004年间下降至略高于1993年的水平。在整个研究期间,女性中两种药物的死亡率均低于男性,且保持相对稳定。1993年至1997年间,每1000患者年的美沙酮死亡人数保持相似,此后下降了四分之三。对于海洛因/吗啡和美沙酮,死亡与查获量均密切相关(男性斯皮尔曼系数:海洛因,P = 0.95,P < 0.001;美沙酮,P = 0.83,P = 0.0013)。
我们的研究表明,“英国体系”能够在不增加死亡风险的情况下大幅扩大治疗规模。2000年以来海洛因/吗啡死亡人数的下降也可能表明美沙酮治疗增加取得了成功。需要死亡率风险数据来确定美沙酮治疗增加是否减少了与毒品相关的死亡。